AIM: Rifaximin is a non-absorbed antibiotic relative of rifampicin. The location of effect and staphylococcal resistance are two recent potential concerns with rifaximin. In this study we evaluate the location of effect of rifaximin as well as the development of staphylococcal rifampicin resistance. METHODS: Rats were divided into three groups. Group 1 gavaged for 10 days with PBS, group 2 gavaged with rifaximin for 10 days, and group 3 gavaged with rifaximin for 10 days and housed for 30 days. In each group, stool was collected daily for quantitative culture of Staphylococcus spp. and coliforms. After euthanasia luminal bacterial counts were determined at multiple gut locations by qPCR. Rifampicin susceptibility was tested on Staphylococcus pre and post rifaximin. RESULTS: At baseline, rats had a median of 2.90 × 10(6) cfu/ml Staphylococcus spp. in stool. After 10 days of rifaximin, this dropped to 1.20 × 10(5) cfu/ml (P < 0.01). With coliform counts, rats had a median of 1.86 × 10(4) cfu/ml at baseline which dropped to 2.2 × 10(3) cfu/ml (P < 0.01) after rifaximin. After cessation of rifaximin, coliform counts recovered within 3 days. When examining the total bacterial counts by qPCR, rifaximin reduced small bowel bacterial levels, but not colon. This reduction was sustained for 30 days. No colonies of Staphylococcus became resistant and only one colony was intermediate. The mean inhibitory concentration for rifampicin was not different before and after rifaximin. CONCLUSION: Staphylococcal spp. fail to demonstrate resistance to rifampicin after rifaximin. The transient reductions in stool coliform counts recover while rifaximin appears to produce durable reductions in duodenal bacteria.
AIM: Rifaximin is a non-absorbed antibiotic relative of rifampicin. The location of effect and staphylococcal resistance are two recent potential concerns with rifaximin. In this study we evaluate the location of effect of rifaximin as well as the development of staphylococcal rifampicin resistance. METHODS:Rats were divided into three groups. Group 1 gavaged for 10 days with PBS, group 2 gavaged with rifaximin for 10 days, and group 3 gavaged with rifaximin for 10 days and housed for 30 days. In each group, stool was collected daily for quantitative culture of Staphylococcus spp. and coliforms. After euthanasia luminal bacterial counts were determined at multiple gut locations by qPCR. Rifampicin susceptibility was tested on Staphylococcus pre and post rifaximin. RESULTS: At baseline, rats had a median of 2.90 × 10(6) cfu/ml Staphylococcus spp. in stool. After 10 days of rifaximin, this dropped to 1.20 × 10(5) cfu/ml (P < 0.01). With coliform counts, rats had a median of 1.86 × 10(4) cfu/ml at baseline which dropped to 2.2 × 10(3) cfu/ml (P < 0.01) after rifaximin. After cessation of rifaximin, coliform counts recovered within 3 days. When examining the total bacterial counts by qPCR, rifaximin reduced small bowel bacterial levels, but not colon. This reduction was sustained for 30 days. No colonies of Staphylococcus became resistant and only one colony was intermediate. The mean inhibitory concentration for rifampicin was not different before and after rifaximin. CONCLUSION: Staphylococcal spp. fail to demonstrate resistance to rifampicin after rifaximin. The transient reductions in stool coliform counts recover while rifaximin appears to produce durable reductions in duodenal bacteria.
Authors: Tamimount Mohammadi; Henk W Reesink; Christina M J E Vandenbroucke-Grauls; Paul H M Savelkoul Journal: J Clin Microbiol Date: 2003-10 Impact factor: 5.948
Authors: Thomas Valentin; Eva Leitner; Angelika Rohn; Ines Zollner-Schwetz; Martin Hoenigl; Helmut J F Salzer; Robert Krause Journal: J Infect Date: 2010-11-10 Impact factor: 6.072
Authors: F Rizzello; P Gionchetti; A Venturi; M Ferretti; S Peruzzo; X Raspanti; M Picard; N Canova; E Palazzini; M Campieri Journal: Eur J Clin Pharmacol Date: 1998-03 Impact factor: 2.953
Authors: W W Hoover; E H Gerlach; D J Hoban; G M Eliopoulos; M A Pfaller; R N Jones Journal: Diagn Microbiol Infect Dis Date: 1993-02 Impact factor: 2.803
Authors: Yujiao Xiang; Zemeng Zhu; Haonan Li; Wei Wang; Zhijun Jiang; Mingyue Zhao; Shuyue Cheng; Fang Pan; Dexiang Liu; Roger C M Ho; Cyrus S H Ho Journal: J Neuroinflammation Date: 2021-11-04 Impact factor: 8.322
Authors: Danica Bajic; Adrian Niemann; Anna-Katharina Hillmer; Raquel Mejias-Luque; Sena Bluemel; Melissa Docampo; Maja C Funk; Elena Tonin; Michael Boutros; Bernd Schnabl; Dirk H Busch; Tsuyoshi Miki; Roland M Schmid; Marcel R M van den Brink; Markus Gerhard; Christoph K Stein-Thoeringer Journal: J Crohns Colitis Date: 2020-10-05 Impact factor: 9.071
Authors: Andrés Acosta; Michael Camilleri; Andrea Shin; Sara Linker Nord; Jessica O'Neill; Amber V Gray; Alan J Lueke; Leslie J Donato; Duane D Burton; Lawrence A Szarka; Alan R Zinsmeister; Pamela L Golden; Anthony Fodor Journal: Clin Transl Gastroenterol Date: 2016-05-26 Impact factor: 4.488
Authors: Ji Young Chang; Seong-Eun Kim; Tae Hun Kim; So-Youn Woo; Min Sun Ryu; Yang-Hee Joo; Ko Eun Lee; Jihyun Lee; Kang Hoon Lee; Chang Mo Moon; Hye-Kyung Jung; Ki-Nam Shim; Sung-Ae Jung Journal: PLoS One Date: 2017-10-05 Impact factor: 3.240
Authors: Elesa Poteres; Nathaniel Hubert; Sudeep Poludasu; Gabriella Brigando; Julia Moore; Kelly Keeler; Allison Isabelli; Iara Cassandra V Ibay; Lauren Alt; Matthew Pytynia; Mae Ciancio; Kristina Martinez-Guryn Journal: Front Physiol Date: 2020-07-07 Impact factor: 4.566